<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080959</url>
  </required_header>
  <id_info>
    <org_study_id>CPL-01-201</org_study_id>
    <nct_id>NCT05080959</nct_id>
  </id_info>
  <brief_title>A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CPL-01 in Postoperative Pain After Open Inguinal Herniorrhaphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cali Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cali Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, randomized, double blind, placebo and active controlled study with an&#xD;
      Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing open&#xD;
      inguinal herniorrhaphy with mesh.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose&#xD;
      Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CPL-01 in the&#xD;
      Management of Postoperative Pain After Open Inguinal Herniorrhaphy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of the NRS-A for pain (Primary Endpoint)</measure>
    <time_frame>0 - 72 hours</time_frame>
    <description>Summary (area under the curve) through 72 hours of the Numeric rating scale with activity score for pain, where 0 is no pain and 10 is worst possible pain</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">305</enrollment>
  <condition>Inguinal Herniorrhaphy</condition>
  <arm_group>
    <arm_group_label>CPL-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPL-01 200mg, 400mg, 600mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mL normal saline (0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPL-01</intervention_name>
    <description>Subjects will receive a single dose</description>
    <arm_group_label>CPL-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naropin 150 MG Per 20 ML Injection</intervention_name>
    <description>Subjects will receive a single dose</description>
    <arm_group_label>Naropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive a single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to sign the informed consent form (ICF) prior to study&#xD;
             participation.&#xD;
&#xD;
          -  In the medical judgment of the Investigator, be a reasonably healthy adult 18 - 75&#xD;
             years of age, inclusive, and American Society of Anesthesiology (ASA) physical Class 1&#xD;
             or 2 at the time of randomization&#xD;
&#xD;
          -  Plan to undergo an elective open inguinal herniorrhaphy with mesh under general&#xD;
             anesthesia without collateral procedures or additional surgeries. Endotracheal&#xD;
             intubation is not required.&#xD;
&#xD;
          -  Have a body mass index ≤ 39 kg/m2.&#xD;
&#xD;
          -  In the judgment of the Investigator, be willing and able to complete study procedures&#xD;
             and pain scales and to communicate meaningfully with study personnel and return for&#xD;
             outpatient follow-up visits as required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has previously undergone herniorrhaphy with the exception of a pediatric herniorrhaphy&#xD;
             prior to 2 years of age.&#xD;
&#xD;
          -  Has undergone 3 or more surgeries within 12 months prior to signing the ICF, other&#xD;
             than for diagnostic procedures (e.g., colonoscopy).&#xD;
&#xD;
          -  Has a history or clinical manifestation of significant medical, neuropsychiatric, or&#xD;
             other condition including a clinically significant existing arrhythmia, bundle branch&#xD;
             block or abnormal electrocardiogram (ECG), myocardial infarction or coronary arterial&#xD;
             bypass graft surgery within the prior 12 months, significant abnormal clinical&#xD;
             laboratory test value, or known bleeding abnormality that could preclude or impair&#xD;
             study participation or interfere with study assessments.&#xD;
&#xD;
          -  Has history or evidence of impaired liver function (e.g., ALT &gt; 3 × upper limit of&#xD;
             normal [ULN] or total bilirubin &gt; 2 × ULN), active hepatic disease, or cirrhosis.&#xD;
&#xD;
          -  Has history or evidence of impaired renal function (e.g., creatinine &gt; 1.5 × ULN).&#xD;
&#xD;
          -  Has a history of malignancy in the past year, with the exception of nonmetastatic&#xD;
             basal cell or squamous cell carcinoma of the skin or localized in situ carcinoma of&#xD;
             the cervix.&#xD;
&#xD;
          -  Has or has had active COVID-19 infection within 3 months prior to surgery.&#xD;
&#xD;
          -  Has a history of, or positive test results for human immunodeficiency virus, hepatitis&#xD;
             B surface antigen, or hepatitis C virus antibody at Screening.&#xD;
&#xD;
          -  Within 7 days prior to the scheduled surgery, be taking any central nervous system (&#xD;
             CNS) active agent as an analgesic adjunct medication, such as anticonvulsants,&#xD;
             gabapentinoids, antidepressants (such as serotonin and norepinephrine reuptake&#xD;
             inhibitors [SNRIs], selective serotonin reuptake inhibitors [SSRIs], and tricyclic&#xD;
             antidepressants), benzodiazepines, sedative-hypnotics, clonidine and other central&#xD;
             alpha-2 agents (e.g., tizanidine), ketamine, or muscle relaxants. These drugs are&#xD;
             permitted if prescribed for non-pain indications and the dose has been stable for at&#xD;
             least 30 days prior to surgery. The dose must remain stable throughout the study.&#xD;
&#xD;
          -  Use of benzodiazepines and non-benzodiazepines (eszopiclone, ramelteon, zaleplon and&#xD;
             zolpidem) is permitted to treat insomnia during the postoperative period.&#xD;
&#xD;
          -  Within 7 days prior to the scheduled surgery and throughout the study, be taking&#xD;
             antiarrhythmics except beta-blockers, digoxin, warfarin (see exception below),&#xD;
             lithium, or aminoglycosides or other antibiotics for an infection (ophthalmic use or&#xD;
             for treatment or prophylaxis of postoperative surgical site infections is permitted).&#xD;
&#xD;
          -  Within 14 days prior to the scheduled surgery and throughout the inpatient period, be&#xD;
             taking or using any cannabidiol-containing products, dietary supplements, or over-the-&#xD;
             counter (OTC) preparations (e.g., chaparral, comfrey, germander, jin bu huan, kava,&#xD;
             pennyroyal, skullcap, St. John's wort, or valerian).&#xD;
&#xD;
          -  Within 28 days prior to the scheduled surgery, has received parenteral or oral&#xD;
             corticosteroid treatment (steroid inhaler for allergy or asthma treatment, topical&#xD;
             steroid for a non-clinically significant skin condition not involving the area of&#xD;
             surgery or ophthalmic steroids are permissible).&#xD;
&#xD;
          -  Is taking an antianginal, antihypertensive agent or diabetic regimen at a dose that&#xD;
             has not been stable for at least 30 days or which is not expected to remain stable&#xD;
             while participating in the study.&#xD;
&#xD;
          -  In the opinion of the Investigator, within the past year has a history of illicit drug&#xD;
             use or prescription medicine or alcohol abuse (regularly drinks &gt; 4 units of alcohol&#xD;
             per day, where 1 unit = 8 ounces beer, 3 ounces of wine, or 1 ounce of spirits).&#xD;
&#xD;
          -  Has a positive alcohol breath/saliva test result indicative of alcohol use, or a&#xD;
             positive urine drug screen result indicative of illicit drug use (unless results can&#xD;
             be explained by a current prescription or acceptable OTC medication at Screening as&#xD;
             determined by the Investigator) at Screening and/or prior to surgery.&#xD;
&#xD;
          -  Has previously participated in a clinical study with CPL-01.&#xD;
&#xD;
          -  Has participated in another clinical trial or used an investigational product within&#xD;
             30 d days or 5 half-lives, whichever is longer, prior to the planned surgery or is&#xD;
             scheduled to receive any other investigational product while participating in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erol Onel, MD</last_name>
    <phone>858-546-0924</phone>
    <email>erolonel@cali-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Chen, PhD</last_name>
    <phone>858-546-0924</phone>
    <email>lchen@cali-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shoals Medical Trials, Inc</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christy Pucket</last_name>
      <email>puckchristy@comcast.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Wiltbank</last_name>
      <email>swiltbank@azresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff DeLeon</last_name>
      <email>jdeleon@act-trials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shruti Kolt</last_name>
      <email>skolte@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Woods</last_name>
      <email>swoods@jbrutah.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

